Abingworth
Abingworth is a leading transatlantic life sciences investment firm that has been transforming cutting-edge science into novel medicines since 1973. With a focus on life sciences, Abingworth provides capital and expertise to top management teams, helping to build world-class companies. The firm has invested in over 185 life science companies, leading to numerous M&A transactions and IPOs. Abingworth operates with offices in London, Menlo Park, and Boston, enabling it to engage closely with entrepreneurs in key biotech hubs. As part of the global investment firm Carlyle, Abingworth continues to expand its reach and impact in the life sciences sector.
Abingworth
38 Jermyn Street, London, SW1Y 6DN
What We Do
Abingworth provides capital and expertise to top caliber management teams building world-class companies.
Abingworth engages in clinical co-development, providing funding and strategic support for clinical studies.
Geographic Focus
Portfolio
Appointed John Chiminski as Chair & Karen Flynn as Independent Director.
#Advanced Therapies
Entered into strategic collaboration with Lilly and completed an oversubscribed US$112M Series C financing.
#Cancer Treatment
Reports positive data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria.
#Biotechnology
Initiated Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis.
#Gene Therapy
Launched with a $180 Million Series A Financing to advance CM313, a potentially best-in-class anti-CD38 monoclonal antibody.
#Therapeutics
Key People
Managing Partner & Head of Abingworth Life Sciences
Managing Partner, Chief Investment Officer & COO
Partner
Partner
Managing Director
Principal
Partner
Chief Financial Officer
Managing Director – Clinical Co-Development
Chair & Managing Partner